Becton Dickinson & Co
BDX: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$686.00 | Vwwyfw | Npcfzdgf |
Becton, Dickinson: Alaris Clearance Important Milestone in Regaining Investor Confidence
We are maintaining our fair value estimate for Becton, Dickinson following the U.S. Food and Drug Administration's clearance of the company's Alaris Infusion System. Our narrow moat rating is unchanged as well.